BioCentury
ARTICLE | Clinical News

SAR302503: Phase III data

May 20, 2013 7:00 AM UTC

Top-line data from the double-blind, international Phase III JAKARTA trial in 289 patients with intermediate-2 or high-risk PMF, PPV-MF or PET-MF showed that once-daily 400 and 500 mg doses of oral SA...